{"transactions":[{"id":749664,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:38:26.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":9000,"derivative":{"exercise_price":4.72,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001193125-26-257564","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526257564/ownership.xml","form_type":"4"}},{"id":1173323,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T21:08:35.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service."}],"balance_after":18000,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0000950170-25-053372","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053372/ownership.xml","form_type":"4"}},{"id":1486928,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-06-07T20:05:15.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) June 6, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors."}],"balance_after":100197,"source":{"system":"sec-edgar","filing":"0000950170-24-070602","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017024070602/ownership.xml","form_type":"4"}},{"id":1895162,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-05-12T21:00:33.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The shares shall vest upon the earlier to occur of (i) May 11, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":65197,"source":{"system":"sec-edgar","filing":"0001209191-23-029095","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000120919123029095/doc4.xml","form_type":"4"}},{"id":2194255,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":124886,"kind":"person","name":"F2 Vision SCS","position":1,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":2,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-05T01:01:26.000Z","date":"2022-08-04","kind":"sale","acquired":false,"shares":25989,"price":14.3056,"value":371788.2384,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.56, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by F2 Vision SCS (\"F2 Vision\"). F2 Vision Management Sarl (\"F2 Vision Management\") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1255963,"source":{"system":"sec-edgar","filing":"0001104659-22-086343","document":"tm2222660-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922086343/tm2222660-1_4seq1.xml","form_type":"4"}},{"id":2194254,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":124886,"kind":"person","name":"F2 Vision SCS","position":1,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":2,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-05T01:01:26.000Z","date":"2022-08-03","kind":"sale","acquired":false,"shares":19129,"price":14.2367,"value":272333.8343,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.95 to $14.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by F2 Vision SCS (\"F2 Vision\"). F2 Vision Management Sarl (\"F2 Vision Management\") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1281952,"source":{"system":"sec-edgar","filing":"0001104659-22-086343","document":"tm2222660-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922086343/tm2222660-1_4seq1.xml","form_type":"4"}},{"id":2194253,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":124886,"kind":"person","name":"F2 Vision SCS","position":1,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":2,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-05T01:01:26.000Z","date":"2022-08-02","kind":"sale","acquired":false,"shares":4792,"price":14.0973,"value":67554.2616,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.99 to $14.17, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (\"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by F2 Vision SCS (\"F2 Vision\"). F2 Vision Management Sarl (\"F2 Vision Management\") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1301081,"source":{"system":"sec-edgar","filing":"0001104659-22-086343","document":"tm2222660-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922086343/tm2222660-1_4seq1.xml","form_type":"4"}},{"id":2199113,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-01T20:35:58.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":3253796,"price":4.61,"value":14999999.56,"ownership":{"direct":false,"nature":"By ElevateBio LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2022, F2 MG Limited (\"F2 MG\"), F2-TPO Investments LLC (\"F2-TPO\"), F2 MC LLC (\"F2 MC\"), F2 Capital I 2020 LLC (\"F2 2020\"), F2 Bioscience AV 2022 LLC (\"F2 2022\") and ElevateBio LLC (\"ElevateBio\") acquired 684,622 shares, 325,379 shares, 1,626,898 shares, 1,393,874 shares, 867,678 shares and 3,253,796 shares, respectively, of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held by ElevateBio. The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":16674766,"source":{"system":"sec-edgar","filing":"0000899243-22-027171","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322027171/doc4.xml","form_type":"4"}},{"id":2199112,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-01T20:35:58.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":867678,"price":4.61,"value":3999995.58,"ownership":{"direct":false,"nature":"By F2 Bioscience AV 2022 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2022, F2 MG Limited (\"F2 MG\"), F2-TPO Investments LLC (\"F2-TPO\"), F2 MC LLC (\"F2 MC\"), F2 Capital I 2020 LLC (\"F2 2020\"), F2 Bioscience AV 2022 LLC (\"F2 2022\") and ElevateBio LLC (\"ElevateBio\") acquired 684,622 shares, 325,379 shares, 1,626,898 shares, 1,393,874 shares, 867,678 shares and 3,253,796 shares, respectively, of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by F2 2022. Globeways Holdings II Limited is the appointed manager of F2 2022 and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 2022. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":867678,"source":{"system":"sec-edgar","filing":"0000899243-22-027171","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322027171/doc4.xml","form_type":"4"}},{"id":2199111,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-01T20:35:58.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":1393874,"price":4.61,"value":6425759.14,"ownership":{"direct":false,"nature":"By F2 Capital I 2020 LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2022, F2 MG Limited (\"F2 MG\"), F2-TPO Investments LLC (\"F2-TPO\"), F2 MC LLC (\"F2 MC\"), F2 Capital I 2020 LLC (\"F2 2020\"), F2 Bioscience AV 2022 LLC (\"F2 2022\") and ElevateBio LLC (\"ElevateBio\") acquired 684,622 shares, 325,379 shares, 1,626,898 shares, 1,393,874 shares, 867,678 shares and 3,253,796 shares, respectively, of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by F2 2020. Globeways Holdings II Limited is the appointed manager of F2 2020 and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 2020. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":4193874,"source":{"system":"sec-edgar","filing":"0000899243-22-027171","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322027171/doc4.xml","form_type":"4"}},{"id":2199110,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-01T20:35:58.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":1626898,"price":4.61,"value":7499999.78,"ownership":{"direct":false,"nature":"By F2 MC, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2022, F2 MG Limited (\"F2 MG\"), F2-TPO Investments LLC (\"F2-TPO\"), F2 MC LLC (\"F2 MC\"), F2 Capital I 2020 LLC (\"F2 2020\"), F2 Bioscience AV 2022 LLC (\"F2 2022\") and ElevateBio LLC (\"ElevateBio\") acquired 684,622 shares, 325,379 shares, 1,626,898 shares, 1,393,874 shares, 867,678 shares and 3,253,796 shares, respectively, of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by F2 MC. Globeways Holdings II Limited is the appointed manager of F2 MC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2038583,"source":{"system":"sec-edgar","filing":"0000899243-22-027171","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322027171/doc4.xml","form_type":"4"}},{"id":2199109,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-01T20:35:58.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":325379,"price":4.61,"value":1499997.19,"ownership":{"direct":false,"nature":"By F2-TPO Investments, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2022, F2 MG Limited (\"F2 MG\"), F2-TPO Investments LLC (\"F2-TPO\"), F2 MC LLC (\"F2 MC\"), F2 Capital I 2020 LLC (\"F2 2020\"), F2 Bioscience AV 2022 LLC (\"F2 2022\") and ElevateBio LLC (\"ElevateBio\") acquired 684,622 shares, 325,379 shares, 1,626,898 shares, 1,393,874 shares, 867,678 shares and 3,253,796 shares, respectively, of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":668072,"source":{"system":"sec-edgar","filing":"0000899243-22-027171","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322027171/doc4.xml","form_type":"4"}},{"id":2199108,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-08-01T20:35:58.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":684622,"price":4.61,"value":3156107.42,"ownership":{"direct":false,"nature":"By F2 MG Limited"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 28, 2022, F2 MG Limited (\"F2 MG\"), F2-TPO Investments LLC (\"F2-TPO\"), F2 MC LLC (\"F2 MC\"), F2 Capital I 2020 LLC (\"F2 2020\"), F2 Bioscience AV 2022 LLC (\"F2 2022\") and ElevateBio LLC (\"ElevateBio\") acquired 684,622 shares, 325,379 shares, 1,626,898 shares, 1,393,874 shares, 867,678 shares and 3,253,796 shares, respectively, of the Issuer's Common Stock in a registered direct offering for a purchase price of $4.61 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2059884,"source":{"system":"sec-edgar","filing":"0000899243-22-027171","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322027171/doc4.xml","form_type":"4"}},{"id":2219984,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T01:24:00.000Z","date":"2022-06-24","kind":"exercise","acquired":false,"shares":35529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":4.3,"expiration_date":"2022-06-30","underlying":"Common Stock","underlying_shares":35529},"source":{"system":"sec-edgar","filing":"0001104659-22-075392","document":"tm2219571-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922075392/tm2219571-1_4seq1.xml","form_type":"4"}},{"id":2219983,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T01:24:00.000Z","date":"2022-06-24","kind":"exercise","acquired":false,"shares":104845,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The shares subject to this option are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":4.3,"expiration_date":"2022-06-30","underlying":"Common Stock","underlying_shares":104845},"source":{"system":"sec-edgar","filing":"0001104659-22-075392","document":"tm2219571-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922075392/tm2219571-1_4seq1.xml","form_type":"4"}},{"id":2219982,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-29T01:24:00.000Z","date":"2022-06-24","kind":"tax_withholding","acquired":false,"shares":45078,"price":13.39,"value":603594.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a net exercise of outstanding stock options. These shares were resold to the Issuer as payment of the exercise price, based on the closing price of the Issuer's common stock on June 24, 2022 of $13.39 per share."}],"balance_after":207803,"source":{"system":"sec-edgar","filing":"0001104659-22-075392","document":"tm2219571-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922075392/tm2219571-1_4seq1.xml","form_type":"4"}},{"id":2219981,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-29T01:24:00.000Z","date":"2022-06-24","kind":"exercise","acquired":true,"shares":35529,"price":4.3,"value":152774.7,"ownership":{"direct":true},"balance_after":252881,"source":{"system":"sec-edgar","filing":"0001104659-22-075392","document":"tm2219571-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922075392/tm2219571-1_4seq1.xml","form_type":"4"}},{"id":2219980,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-29T01:24:00.000Z","date":"2022-06-24","kind":"exercise","acquired":true,"shares":104845,"price":4.3,"value":450833.5,"ownership":{"direct":true},"balance_after":217352,"source":{"system":"sec-edgar","filing":"0001104659-22-075392","document":"tm2219571-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922075392/tm2219571-1_4seq1.xml","form_type":"4"}},{"id":2222716,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":1,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":2,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-23T22:47:26.000Z","date":"2022-06-23","kind":"sale","acquired":false,"shares":29631,"price":13.0036,"value":385309.6716,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.72 to $13.35, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by F2 Bioscience I 2017 Limited (\"F2 Bioscience 2017\"). Globeways Holdings Limited (\"Globeways\") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":537392,"source":{"system":"sec-edgar","filing":"0001104659-22-073980","document":"tm2219298-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922073980/tm2219298-1_4seq1.xml","form_type":"4"}},{"id":2222715,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":1,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":2,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-23T22:47:26.000Z","date":"2022-06-22","kind":"sale","acquired":false,"shares":49953,"price":12.7035,"value":634577.9355,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.35 to $12.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by F2 Bioscience I 2017 Limited (\"F2 Bioscience 2017\"). Globeways Holdings Limited (\"Globeways\") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":567023,"source":{"system":"sec-edgar","filing":"0001104659-22-073980","document":"tm2219298-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922073980/tm2219298-1_4seq1.xml","form_type":"4"}},{"id":2222714,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":1,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":2,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-06-23T22:47:26.000Z","date":"2022-06-21","kind":"sale","acquired":false,"shares":22319,"price":12.7662,"value":284928.8178,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.58 to $12.99, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (\"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by F2 Bioscience I 2017 Limited (\"F2 Bioscience 2017\"). Globeways Holdings Limited (\"Globeways\") is the appointed manager of F2 Bioscience 2017. Dr. Morana Jovan-Embiricos is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":616976,"source":{"system":"sec-edgar","filing":"0001104659-22-073980","document":"tm2219298-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922073980/tm2219298-1_4seq1.xml","form_type":"4"}},{"id":2263867,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-19T20:28:58.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable upon the earlier to occur of (i) May 17, 2023 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":27500,"derivative":{"exercise_price":4.6,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0000899243-22-018836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924322018836/doc4.xml","form_type":"4"}},{"id":2269833,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":124886,"kind":"person","name":"F2 Vision SCS","position":1,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":2,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T00:54:53.000Z","date":"2022-05-16","kind":"sale","acquired":false,"shares":35158,"price":11.2301,"value":394827.8558,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by F2 Vision SCS (\"F2 Vision\"). F2 Vision Management Sarl (\"F2 Vision Management\") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1305873,"source":{"system":"sec-edgar","filing":"0001104659-22-061591","document":"tm2215669-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922061591/tm2215669-1_4seq1.xml","form_type":"4"}},{"id":2269832,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":124886,"kind":"person","name":"F2 Vision SCS","position":1,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":2,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T00:54:53.000Z","date":"2022-05-13","kind":"sale","acquired":false,"shares":34189,"price":10.481,"value":358334.909,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.40 to $10.65, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by F2 Vision SCS (\"F2 Vision\"). F2 Vision Management Sarl (\"F2 Vision Management\") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1341031,"source":{"system":"sec-edgar","filing":"0001104659-22-061591","document":"tm2215669-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922061591/tm2215669-1_4seq1.xml","form_type":"4"}},{"id":2269831,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":124886,"kind":"person","name":"F2 Vision SCS","position":1,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":2,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T00:54:53.000Z","date":"2022-05-13","kind":"sale","acquired":false,"shares":85319,"price":9.9631,"value":850041.7289,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.40 to $10.395, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by F2 Vision SCS (\"F2 Vision\"). F2 Vision Management Sarl (\"F2 Vision Management\") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1375220,"source":{"system":"sec-edgar","filing":"0001104659-22-061591","document":"tm2215669-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922061591/tm2215669-1_4seq1.xml","form_type":"4"}},{"id":2269830,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":124886,"kind":"person","name":"F2 Vision SCS","position":1,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":2,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-05-17T00:54:53.000Z","date":"2022-05-12","kind":"sale","acquired":false,"shares":264072,"price":9.2497,"value":2442586.7784,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.58, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (\"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by F2 Vision SCS (\"F2 Vision\"). F2 Vision Management Sarl (\"F2 Vision Management\") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1460539,"source":{"system":"sec-edgar","filing":"0001104659-22-061591","document":"tm2215669-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000110465922061591/tm2215669-1_4seq1.xml","form_type":"4"}},{"id":2317468,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-25T23:32:00.000Z","date":"2021-09-16","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 7,800 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 25, 2022 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date."}],"balance_after":7800,"derivative":{"exercise_price":28.8,"expiration_date":"2031-09-15","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0000899243-22-012373","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924322012373/doc4.xml","form_type":"4"}},{"id":2435679,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":124886,"kind":"person","name":"F2 Vision SCS","position":1,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":2,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-13T22:22:57.000Z","date":"2022-01-11","kind":"other","acquired":false,"shares":1187734,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 11, 2022, F2 Vision SCS (\"F2 Vision\") distributed, for no consideration, 1,187,734 shares of Common Stock of the Issuer (the \"Shares\") to certain of its limited partners representing such limited partner's pro rata interest in the shares held by F2 Vision.  The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 11, 2022, F2 Vision SCS (\"F2 Vision\") distributed, for no consideration, 1,187,734 shares of Common Stock of the Issuer (the \"Shares\") to certain of its limited partners representing such limited partner's pro rata interest in the shares held by F2 Vision.  The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by F2 Vision. F2 Vision Management Sarl (\"F2 Vision Management\") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1724611,"source":{"system":"sec-edgar","filing":"0000899243-22-001926","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924322001926/doc4.xml","form_type":"4"}},{"id":2512922,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-15T22:17:43.000Z","date":"2021-11-10","kind":"sale","acquired":false,"shares":120,"price":24.765,"value":2971.8,"ownership":{"direct":false,"nature":"By F2-TPO Investments, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by F2 MG Limited (\"F2 MG\") and F2-TPO Investments, LLC (\"F2-TPO\") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.78, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":342693,"source":{"system":"sec-edgar","filing":"0000899243-21-044619","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321044619/doc4.xml","form_type":"4"}},{"id":2512921,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-15T22:17:43.000Z","date":"2021-11-10","kind":"sale","acquired":false,"shares":680,"price":24.765,"value":16840.2,"ownership":{"direct":false,"nature":"By F2 MG Limited"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by F2 MG Limited (\"F2 MG\") and F2-TPO Investments, LLC (\"F2-TPO\") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.78, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1375262,"source":{"system":"sec-edgar","filing":"0000899243-21-044619","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321044619/doc4.xml","form_type":"4"}},{"id":2519823,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-09T23:43:58.000Z","date":"2021-11-09","kind":"sale","acquired":false,"shares":572,"price":24.7882,"value":14178.8504,"ownership":{"direct":false,"nature":"By F2-TPO Investments, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by F2 MG Limited (\"F2 MG\") and F2-TPO Investments, LLC (\"F2-TPO\") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.825, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":342813,"source":{"system":"sec-edgar","filing":"0000899243-21-043670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321043670/doc4.xml","form_type":"4"}},{"id":2519822,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-09T23:43:58.000Z","date":"2021-11-09","kind":"sale","acquired":false,"shares":3243,"price":24.7882,"value":80388.1326,"ownership":{"direct":false,"nature":"By F2 MG Limited"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by F2 MG Limited (\"F2 MG\") and F2-TPO Investments, LLC (\"F2-TPO\") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.825, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1375942,"source":{"system":"sec-edgar","filing":"0000899243-21-043670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321043670/doc4.xml","form_type":"4"}},{"id":2519821,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-09T23:43:58.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":1257,"price":24.8047,"value":31179.5079,"ownership":{"direct":false,"nature":"By F2-TPO Investments, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by F2 MG Limited (\"F2 MG\") and F2-TPO Investments, LLC (\"F2-TPO\") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":343385,"source":{"system":"sec-edgar","filing":"0000899243-21-043670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321043670/doc4.xml","form_type":"4"}},{"id":2519820,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-09T23:43:58.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":7124,"price":24.8047,"value":176708.6828,"ownership":{"direct":false,"nature":"By F2 MG Limited"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by F2 MG Limited (\"F2 MG\") and F2-TPO Investments, LLC (\"F2-TPO\") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1379185,"source":{"system":"sec-edgar","filing":"0000899243-21-043670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321043670/doc4.xml","form_type":"4"}},{"id":2531919,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-29T21:02:36.000Z","date":"2021-10-27","kind":"sale","acquired":false,"shares":330,"price":24.7775,"value":8176.575,"ownership":{"direct":false,"nature":"By F2-TPO Investments, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by F2 MG Limited (\"F2 MG\") and F2-TPO Investments, LLC (\"F2-TPO\") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.805, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":344642,"source":{"system":"sec-edgar","filing":"0000899243-21-042033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321042033/doc4.xml","form_type":"4"}},{"id":2531918,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-29T21:02:36.000Z","date":"2021-10-27","kind":"sale","acquired":false,"shares":1870,"price":24.7775,"value":46333.925,"ownership":{"direct":false,"nature":"By F2 MG Limited"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by F2 MG Limited (\"F2 MG\") and F2-TPO Investments, LLC (\"F2-TPO\") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.805, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1386309,"source":{"system":"sec-edgar","filing":"0000899243-21-042033","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321042033/doc4.xml","form_type":"4"}},{"id":2535590,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-25T22:24:49.000Z","date":"2021-10-25","kind":"sale","acquired":false,"shares":1165,"price":24.8183,"value":28913.3195,"ownership":{"direct":false,"nature":"By F2-TPO Investments, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by F2 MG Limited (\"F2 MG\") and F2-TPO Investments, LLC (\"F2-TPO\") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $25.05, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":344972,"source":{"system":"sec-edgar","filing":"0000899243-21-041467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321041467/doc4.xml","form_type":"4"}},{"id":2535589,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-25T22:24:49.000Z","date":"2021-10-25","kind":"sale","acquired":false,"shares":6604,"price":24.8183,"value":163900.0532,"ownership":{"direct":false,"nature":"By F2 MG Limited"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by F2 MG Limited (\"F2 MG\") and F2-TPO Investments, LLC (\"F2-TPO\") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $25.05, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1388179,"source":{"system":"sec-edgar","filing":"0000899243-21-041467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321041467/doc4.xml","form_type":"4"}},{"id":2535588,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-25T22:24:49.000Z","date":"2021-10-22","kind":"sale","acquired":false,"shares":859,"price":24.7697,"value":21277.1723,"ownership":{"direct":false,"nature":"By F2-TPO Investments, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by F2 MG Limited (\"F2 MG\") and F2-TPO Investments, LLC (\"F2-TPO\") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.85, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":346137,"source":{"system":"sec-edgar","filing":"0000899243-21-041467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321041467/doc4.xml","form_type":"4"}},{"id":2535587,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-25T22:24:49.000Z","date":"2021-10-22","kind":"sale","acquired":false,"shares":4864,"price":24.7697,"value":120479.8208,"ownership":{"direct":false,"nature":"By F2 MG Limited"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by F2 MG Limited (\"F2 MG\") and F2-TPO Investments, LLC (\"F2-TPO\") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.85, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1394783,"source":{"system":"sec-edgar","filing":"0000899243-21-041467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321041467/doc4.xml","form_type":"4"}},{"id":2535586,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-25T22:24:49.000Z","date":"2021-10-21","kind":"sale","acquired":false,"shares":15,"price":24.75,"value":371.25,"ownership":{"direct":false,"nature":"By F2-TPO Investments, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by F2 MG Limited (\"F2 MG\") and F2-TPO Investments, LLC (\"F2-TPO\") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":346996,"source":{"system":"sec-edgar","filing":"0000899243-21-041467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321041467/doc4.xml","form_type":"4"}},{"id":2535585,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-10-25T22:24:49.000Z","date":"2021-10-21","kind":"sale","acquired":false,"shares":85,"price":24.75,"value":2103.75,"ownership":{"direct":false,"nature":"By F2 MG Limited"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by F2 MG Limited (\"F2 MG\") and F2-TPO Investments, LLC (\"F2-TPO\") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1399647,"source":{"system":"sec-edgar","filing":"0000899243-21-041467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321041467/doc4.xml","form_type":"4"}},{"id":2693585,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-27T20:45:41.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable upon the earlier to occur of (i) May 25, 2022 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":22500,"derivative":{"exercise_price":21.51,"expiration_date":"2031-05-24","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000899243-21-020859","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924321020859/doc4.xml","form_type":"4"}},{"id":2906899,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":1511966,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are owned directly by F2 MC, LLC (\"F2 MC\"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":214798},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906898,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":503988,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are owned directly by F2 Bio TD, LLC (\"F2 Bio\"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":71599},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906897,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":1007977,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are owned directly by F2 MG Limited (\"F2 MG\"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":143198},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906896,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":503988,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are owned directly by F2-TPO Investments, LLC (\"F2-TPO\"). Globeways Holdings II Limited (\"Globeways II\") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":71599},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906895,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":1282051,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are owned directly by F2 MG Limited (\"F2 MG\"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":182135},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906894,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":3205128,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are owned directly by F2-TPO Investments, LLC (\"F2-TPO\"). Globeways Holdings II Limited (\"Globeways II\") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":455338},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906893,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":4500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are owned directly by F2 Bioscience I 2017 Limited (\"F2 Bioscience 2017\"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":639295},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906892,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":20500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are owned directly by F2 Vision SCS (\"F2 Vision\"). F2 Vision Management Sarl (\"F2 Vision Management\") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2912345},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906891,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Convertible Preferred Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":8000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Globeways Holdings Limited (\"Globeways\"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1136525},"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906890,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"purchase","acquired":true,"shares":104762,"price":21,"value":2200002.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These securities are owned directly by F2 GC LLC (\"F2 GC\"). Globeways II is the appointed manager of F2 GC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 GC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":104762,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906889,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"purchase","acquired":true,"shares":95238,"price":21,"value":1999998.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are owned directly by F2-TPO Investments, LLC (\"F2-TPO\"). Globeways Holdings II Limited (\"Globeways II\") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":622175,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906888,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":214798,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are owned directly by F2 MC, LLC (\"F2 MC\"). Globeways II is the appointed manager of F2 MC. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":214798,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906887,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":71599,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are owned directly by F2 Bio TD, LLC (\"F2 Bio\"). Globeways II is the appointed manager of F2 Bio. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bio. . The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":71599,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906886,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":143198,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are owned directly by F2 MG Limited (\"F2 MG\"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":325333,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906885,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":71599,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are owned directly by F2-TPO Investments, LLC (\"F2-TPO\"). Globeways Holdings II Limited (\"Globeways II\") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":526937,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906884,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":182135,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are owned directly by F2 MG Limited (\"F2 MG\"). Globeways is the appointed manager of F2 MG. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":182135,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906883,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":455338,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are owned directly by F2-TPO Investments, LLC (\"F2-TPO\"). Globeways Holdings II Limited (\"Globeways II\") is the appointed manager of F2-TPO. The Reporting Person is the founding director of Globeways II and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":455338,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906882,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":639295,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are owned directly by F2 Bioscience I 2017 Limited (\"F2 Bioscience 2017\"). Globeways is the appointed manager of F2 Bioscience 2017. The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":639295,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906881,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":2912345,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are owned directly by F2 Vision SCS (\"F2 Vision\"). F2 Vision Management Sarl (\"F2 Vision Management\") is the appointed manager of F2 Vision. The Reporting Person is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2912345,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":2906880,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124886,"kind":"person","name":"F2 Vision SCS","position":3,"cik":"0001838409","reported_name":"F2 Vision SCS","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":125896,"kind":"organization","name":"F2 Bioscience I 2017 Ltd","position":4,"cik":"0001838573","reported_name":"F2 Bioscience I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":5,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":6,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143778,"kind":"organization","name":"F2 Bio TD, LLC","position":7,"cik":"0001838330","reported_name":"F2 Bio TD, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124860,"kind":"person","name":"F2 MC, LLC","position":8,"cik":"0001838426","reported_name":"F2 MC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":143779,"kind":"organization","name":"F2 GC, LLC","position":9,"cik":"0001840637","reported_name":"F2 GC, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:30:41.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":1136525,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (the \"Preferred Stock') converted into Common Stock of the Issuer on a 1-for-7.0390 basis at the closing of the Issuer's initial public offering on January 12, 2021.  The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by Globeways Holdings Limited (\"Globeways\"). The Reporting Person is the founding director of Globeways and has the sole power to vote upon the acquisition, holding and disposal of all shares held by Globeways. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1136525,"source":{"system":"sec-edgar","filing":"0000899243-21-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575745/000089924321002048/doc4.xml","form_type":"4"}},{"id":3066015,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-08-06T10:06:29.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":613496,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shared held by F2 MC, LLC (\"F2 MC\"). Globeways Holdings II Limited is the appointed manager of F2 MC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":411685},"source":{"system":"sec-edgar","filing":"0000899243-20-021597","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021597/doc4.xml","form_type":"4"}},{"id":3066014,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-08-06T10:06:29.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":2085889,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by F2 MG Limited (\"F2 MG\"). Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1399732},"source":{"system":"sec-edgar","filing":"0000899243-20-021597","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021597/doc4.xml","form_type":"4"}},{"id":3066013,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2020-08-06T10:06:29.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":368098,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by F2-TPO Investments, LLC (\"F2-TPO\"). Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":247011},"source":{"system":"sec-edgar","filing":"0000899243-20-021597","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021597/doc4.xml","form_type":"4"}},{"id":3066012,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2020-08-06T10:06:29.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":20000000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by ElevateBio LLC (\"ElevateBio\"). The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13420970},"source":{"system":"sec-edgar","filing":"0000899243-20-021597","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021597/doc4.xml","form_type":"4"}},{"id":3066011,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-06T10:06:29.000Z","date":"2020-08-03","kind":"purchase","acquired":true,"shares":2800000,"price":17,"value":47600000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by F2 Capital I 2020 LLC (\"F2 2020\"). Globeways Holdings II Limited is the appointed manager of F2 2020 and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 2020. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2800000,"source":{"system":"sec-edgar","filing":"0000899243-20-021597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021597/doc4.xml","form_type":"4"}},{"id":3066010,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-06T10:06:29.000Z","date":"2020-08-03","kind":"purchase","acquired":true,"shares":100000,"price":17,"value":1700000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by F2-TPO Investments, LLC (\"F2-TPO\"). Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":347011,"source":{"system":"sec-edgar","filing":"0000899243-20-021597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021597/doc4.xml","form_type":"4"}},{"id":3066009,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-06T10:06:29.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":411685,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shared held by F2 MC, LLC (\"F2 MC\"). Globeways Holdings II Limited is the appointed manager of F2 MC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MC. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":411685,"source":{"system":"sec-edgar","filing":"0000899243-20-021597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021597/doc4.xml","form_type":"4"}},{"id":3066008,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-06T10:06:29.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":1399732,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by F2 MG Limited (\"F2 MG\"). Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1399732,"source":{"system":"sec-edgar","filing":"0000899243-20-021597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021597/doc4.xml","form_type":"4"}},{"id":3066007,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-06T10:06:29.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":247011,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by F2-TPO Investments, LLC (\"F2-TPO\"). Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":247011,"source":{"system":"sec-edgar","filing":"0000899243-20-021597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021597/doc4.xml","form_type":"4"}},{"id":3066006,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-08-06T10:06:29.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":13420970,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of convertible preferred stock automatically converted into the Issuer's Common Stock on a one-for-1.49021 basis upon the closing of the Issuer's initial public offering on August 3, 2020 and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by ElevateBio LLC (\"ElevateBio\"). The Reporting Person is a director of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":13420970,"source":{"system":"sec-edgar","filing":"0000899243-20-021597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320021597/doc4.xml","form_type":"4"}},{"id":3072600,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-31T22:44:18.000Z","date":"2020-07-29","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) July 29, 2021, and (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":22500,"derivative":{"exercise_price":17,"expiration_date":"2030-07-29","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000899243-20-020932","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000089924320020932/doc4.xml","form_type":"4"}},{"id":3334797,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152992,"kind":"organization","name":"F2 Bioscience II 2017 Ltd","position":7,"cik":"0001767388","reported_name":"F2 Bioscience II 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":8,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152993,"kind":"organization","name":"F2 BBG LLC","position":9,"cik":"0001767415","reported_name":"F2 BBG LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152994,"kind":"organization","name":"F2 Capital I 2019, LLC","position":10,"cik":"0001767418","reported_name":"F2 Capital I 2019, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-20T17:31:30.000Z","date":"2019-12-20","kind":"other","acquired":false,"shares":13847,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents a pro-rata in-kind distribution of common stock by F2 BBG LLC without consideration to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported securities are owned directly by F2 BBG LLC. Globeways Holdings II Limited is the appointed manager of F2 BBG LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 BBG LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":161024,"source":{"system":"sec-edgar","filing":"0000899243-19-029791","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1767388/000089924319029791/doc4.xml","form_type":"4"}},{"id":3334796,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152992,"kind":"organization","name":"F2 Bioscience II 2017 Ltd","position":7,"cik":"0001767388","reported_name":"F2 Bioscience II 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":8,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152993,"kind":"organization","name":"F2 BBG LLC","position":9,"cik":"0001767415","reported_name":"F2 BBG LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152994,"kind":"organization","name":"F2 Capital I 2019, LLC","position":10,"cik":"0001767418","reported_name":"F2 Capital I 2019, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-20T17:31:30.000Z","date":"2019-12-20","kind":"other","acquired":false,"shares":586153,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents a pro-rata in-kind distribution of common stock by F2 Capital I 2015 Limited without consideration to its partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":713723,"source":{"system":"sec-edgar","filing":"0000899243-19-029791","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1767388/000089924319029791/doc4.xml","form_type":"4"}},{"id":3334795,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152992,"kind":"organization","name":"F2 Bioscience II 2017 Ltd","position":7,"cik":"0001767388","reported_name":"F2 Bioscience II 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":8,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152993,"kind":"organization","name":"F2 BBG LLC","position":9,"cik":"0001767415","reported_name":"F2 BBG LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152994,"kind":"organization","name":"F2 Capital I 2019, LLC","position":10,"cik":"0001767418","reported_name":"F2 Capital I 2019, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-20T17:31:30.000Z","date":"2019-12-19","kind":"sale","acquired":false,"shares":35323,"price":16.4714,"value":581819.2622,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":155986,"source":{"system":"sec-edgar","filing":"0000899243-19-029791","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1767388/000089924319029791/doc4.xml","form_type":"4"}},{"id":3334794,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152992,"kind":"organization","name":"F2 Bioscience II 2017 Ltd","position":7,"cik":"0001767388","reported_name":"F2 Bioscience II 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":8,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152993,"kind":"organization","name":"F2 BBG LLC","position":9,"cik":"0001767415","reported_name":"F2 BBG LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152994,"kind":"organization","name":"F2 Capital I 2019, LLC","position":10,"cik":"0001767418","reported_name":"F2 Capital I 2019, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-20T17:31:30.000Z","date":"2019-12-19","kind":"sale","acquired":false,"shares":6642,"price":16.4714,"value":109403.0388,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":82575,"source":{"system":"sec-edgar","filing":"0000899243-19-029791","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1767388/000089924319029791/doc4.xml","form_type":"4"}},{"id":3334793,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152992,"kind":"organization","name":"F2 Bioscience II 2017 Ltd","position":7,"cik":"0001767388","reported_name":"F2 Bioscience II 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":8,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152993,"kind":"organization","name":"F2 BBG LLC","position":9,"cik":"0001767415","reported_name":"F2 BBG LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152994,"kind":"organization","name":"F2 Capital I 2019, LLC","position":10,"cik":"0001767418","reported_name":"F2 Capital I 2019, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-20T17:31:30.000Z","date":"2019-12-18","kind":"sale","acquired":false,"shares":2433,"price":17.006,"value":41375.598,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by F2 Bioscience II 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Bioscience II 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Bioscience II 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":191309,"source":{"system":"sec-edgar","filing":"0000899243-19-029791","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1767388/000089924319029791/doc4.xml","form_type":"4"}},{"id":3334792,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152992,"kind":"organization","name":"F2 Bioscience II 2017 Ltd","position":7,"cik":"0001767388","reported_name":"F2 Bioscience II 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":8,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152993,"kind":"organization","name":"F2 BBG LLC","position":9,"cik":"0001767415","reported_name":"F2 BBG LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152994,"kind":"organization","name":"F2 Capital I 2019, LLC","position":10,"cik":"0001767418","reported_name":"F2 Capital I 2019, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-20T17:31:30.000Z","date":"2019-12-18","kind":"sale","acquired":false,"shares":458,"price":17.006,"value":7788.748,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":89217,"source":{"system":"sec-edgar","filing":"0000899243-19-029791","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1767388/000089924319029791/doc4.xml","form_type":"4"}},{"id":3345419,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-11T19:09:41.000Z","date":"2019-12-11","kind":"sale","acquired":false,"shares":4153,"price":17.6525,"value":73310.8325,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":1299876,"source":{"system":"sec-edgar","filing":"0000899243-19-028968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/doc4.xml","form_type":"4"}},{"id":3345418,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-11T19:09:41.000Z","date":"2019-12-11","kind":"sale","acquired":false,"shares":1054,"price":17.6525,"value":18605.735,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":330238,"source":{"system":"sec-edgar","filing":"0000899243-19-028968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/doc4.xml","form_type":"4"}},{"id":3345417,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-11T19:09:41.000Z","date":"2019-12-11","kind":"sale","acquired":false,"shares":1381,"price":17.6525,"value":24378.1025,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":432319,"source":{"system":"sec-edgar","filing":"0000899243-19-028968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/doc4.xml","form_type":"4"}},{"id":3345416,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-11T19:09:41.000Z","date":"2019-12-11","kind":"sale","acquired":false,"shares":1155,"price":17.6525,"value":20388.6375,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":361665,"source":{"system":"sec-edgar","filing":"0000899243-19-028968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/doc4.xml","form_type":"4"}},{"id":3345415,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-11T19:09:41.000Z","date":"2019-12-10","kind":"sale","acquired":false,"shares":30475,"price":17.6232,"value":537067.02,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":1304029,"source":{"system":"sec-edgar","filing":"0000899243-19-028968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/doc4.xml","form_type":"4"}},{"id":3345414,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-11T19:09:41.000Z","date":"2019-12-10","kind":"sale","acquired":false,"shares":7741,"price":17.6232,"value":136421.1912,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":331292,"source":{"system":"sec-edgar","filing":"0000899243-19-028968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/doc4.xml","form_type":"4"}},{"id":3345413,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-11T19:09:41.000Z","date":"2019-12-10","kind":"sale","acquired":false,"shares":10135,"price":17.6232,"value":178611.132,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":433700,"source":{"system":"sec-edgar","filing":"0000899243-19-028968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/doc4.xml","form_type":"4"}},{"id":3345412,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-11T19:09:41.000Z","date":"2019-12-10","kind":"sale","acquired":false,"shares":8479,"price":17.6232,"value":149427.1128,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":362820,"source":{"system":"sec-edgar","filing":"0000899243-19-028968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/doc4.xml","form_type":"4"}},{"id":3345411,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-11T19:09:41.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":75067,"price":17.6511,"value":1325015.1237,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":1334504,"source":{"system":"sec-edgar","filing":"0000899243-19-028968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/doc4.xml","form_type":"4"}},{"id":3345410,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-11T19:09:41.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":19070,"price":17.6511,"value":336606.477,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":339033,"source":{"system":"sec-edgar","filing":"0000899243-19-028968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/doc4.xml","form_type":"4"}},{"id":3345409,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-11T19:09:41.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":24966,"price":17.6511,"value":440677.3626,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":443835,"source":{"system":"sec-edgar","filing":"0000899243-19-028968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/doc4.xml","form_type":"4"}},{"id":3345408,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-12-11T19:09:41.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":20886,"price":17.6511,"value":368660.8746,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":371299,"source":{"system":"sec-edgar","filing":"0000899243-19-028968","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319028968/doc4.xml","form_type":"4"}},{"id":3388722,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-24T18:36:30.000Z","date":"2019-10-22","kind":"sale","acquired":false,"shares":2085,"price":15.1571,"value":31602.5535,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":1409571,"source":{"system":"sec-edgar","filing":"0000899243-19-025909","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319025909/doc4.xml","form_type":"4"}},{"id":3388721,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-24T18:36:30.000Z","date":"2019-10-22","kind":"sale","acquired":false,"shares":530,"price":15.1571,"value":8033.263,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":358103,"source":{"system":"sec-edgar","filing":"0000899243-19-025909","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319025909/doc4.xml","form_type":"4"}},{"id":3388720,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-24T18:36:30.000Z","date":"2019-10-22","kind":"sale","acquired":false,"shares":693,"price":15.1571,"value":10503.8703,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are owned directly by F2-TPO Investments, LLC. Globeways Holdings II Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":392185,"source":{"system":"sec-edgar","filing":"0000899243-19-025909","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319025909/doc4.xml","form_type":"4"}},{"id":3388719,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-24T18:36:30.000Z","date":"2019-10-22","kind":"sale","acquired":false,"shares":580,"price":15.1571,"value":8791.118,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by F2 MG Limited. Globeways Holdings Limited is the appointed manager of F2 MG Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":392185,"source":{"system":"sec-edgar","filing":"0000899243-19-025909","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319025909/doc4.xml","form_type":"4"}},{"id":3407145,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152993,"kind":"organization","name":"F2 BBG LLC","position":8,"cik":"0001767415","reported_name":"F2 BBG LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152994,"kind":"organization","name":"F2 Capital I 2019, LLC","position":9,"cik":"0001767418","reported_name":"F2 Capital I 2019, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-24T20:27:35.000Z","date":"2019-09-23","kind":"sale","acquired":false,"shares":5516,"price":17.3114,"value":95489.6824,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The reported securities are owned directly by F2 Capital I 2015 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2015 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2015 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":1411656,"source":{"system":"sec-edgar","filing":"0000899243-19-024208","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/doc4.xml","form_type":"4"}},{"id":3407144,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152993,"kind":"organization","name":"F2 BBG LLC","position":8,"cik":"0001767415","reported_name":"F2 BBG LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152994,"kind":"organization","name":"F2 Capital I 2019, LLC","position":9,"cik":"0001767418","reported_name":"F2 Capital I 2019, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-24T20:27:35.000Z","date":"2019-09-23","kind":"sale","acquired":false,"shares":1401,"price":17.3114,"value":24253.2714,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The reported securities are owned directly by F2 Capital I 2017 Limited. Globeways Holdings Limited is the appointed manager of F2 Capital I 2017 Limited and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2017 Limited. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":358633,"source":{"system":"sec-edgar","filing":"0000899243-19-024208","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/doc4.xml","form_type":"4"}},{"id":3407143,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152993,"kind":"organization","name":"F2 BBG LLC","position":8,"cik":"0001767415","reported_name":"F2 BBG LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152994,"kind":"organization","name":"F2 Capital I 2019, LLC","position":9,"cik":"0001767418","reported_name":"F2 Capital I 2019, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-24T20:27:35.000Z","date":"2019-09-23","kind":"sale","acquired":false,"shares":1835,"price":17.3114,"value":31766.419,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities are owned directly F2-TPO Investments, LLC. Globeways Holdings Limited is the appointed manager of F2-TPO Investments, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO Investments, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":469464,"source":{"system":"sec-edgar","filing":"0000899243-19-024208","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/doc4.xml","form_type":"4"}},{"id":3407142,"issuer":{"id":94327,"kind":"organization","name":"TCR2 THERAPEUTICS INC.","symbol":"TCRR"},"owners":[{"id":41364,"kind":"person","name":"Jovan-Embiricos Morana","position":1,"cik":"0001575745","reported_name":"Jovan-Embiricos Morana","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124858,"kind":"person","name":"Globeways Holdings Ltd","position":2,"cik":"0001600769","reported_name":"Globeways Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124863,"kind":"person","name":"Globeways Holdings II Ltd","position":3,"cik":"0001768161","reported_name":"Globeways Holdings II Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152990,"kind":"organization","name":"F2 Capital I 2015 Ltd","position":4,"cik":"0001767391","reported_name":"F2 Capital I 2015 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152991,"kind":"organization","name":"F2 Captial I 2017 Ltd","position":5,"cik":"0001767390","reported_name":"F2 Captial I 2017 Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124857,"kind":"person","name":"F2 MG Ltd","position":6,"cik":"0001767396","reported_name":"F2 MG Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124859,"kind":"person","name":"F2 - TPO Investments LLC","position":7,"cik":"0001767397","reported_name":"F2 - TPO Investments LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152993,"kind":"organization","name":"F2 BBG LLC","position":8,"cik":"0001767415","reported_name":"F2 BBG LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":152994,"kind":"organization","name":"F2 Capital I 2019, LLC","position":9,"cik":"0001767418","reported_name":"F2 Capital I 2019, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-09-24T20:27:35.000Z","date":"2019-09-23","kind":"sale","acquired":false,"shares":351,"price":17.3114,"value":6076.3014,"ownership":{"direct":false,"nature":"By Fund"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are owned directly by F2 Capital I 2019, LLC. Globeways Holdings II Limited is the appointed manager of F2 Capital I 2019, LLC and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Capital I 2019, LLC. Morana Jovan-Embiricos is the founding director and shareholder of Globeways Holdings II Limited and has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein."}],"balance_after":89675,"source":{"system":"sec-edgar","filing":"0000899243-19-024208","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1750019/000089924319024208/doc4.xml","form_type":"4"}}],"next_cursor":"2019-09-24T20:27:35.000000Z,3407142"}